Curtis J Henrich

US Patent:

20100267652, Oct 21, 2010

Filed:

Nov 5, 2008

Appl. No.:

12/742039

Inventors:

Curtis J. Henrich - Rockville MD, US
Heidi R. Bokesch - Frederick MD, US
Susan E. Bates - Bethesda MD, US
Robert W. Robey - Laurel MD, US
Suneet Shukla - Rockville MD, US
Suresh V. Ambudkar - Gaithersburg MD, US
Michael C. Dean - Frederick MD, US
James B. McMahon - Frederick MD, US

International Classification:

A61K 31/7042
A61K 31/4985
A61K 31/519
A61K 31/4439
A61K 31/40
A61K 31/295
A61P 35/04

US Classification:

514 26, 514250, 5142621, 514341, 514418, 514501

Abstract:

Disclosed are methods of enhancing the chemotherapeutic treatment of tumor cells, reducing resistance of a cancer cell to a chemotherapeutic agent, a method of inhibiting ABCG2 or MRP1 in a mammal afflicted with cancer, and a method of increasing the bioavailability of an ABCG2 substrate drug in a mammal. The methods comprise administering peliomycin and other compounds described herein.

US Patent:

20100317732, Dec 16, 2010

Filed:

Dec 29, 2008

Appl. No.:

12/811144

Inventors:

Curtis J. Henrich - Rockville MD, US
Heidi R. Bokesch - Frederick MD, US
Laura K. Cartner - Middletown MD, US
Richard W. Fuller - Fairfield PA, US
Kirk R. Gustafson - Frederick MD, US
Kentaro Takada - Yokohama, JP
James B. McMahon - Frederick MD, US
Susan E. Bates - Bethesda MD, US
Robert W. Robey - Laurel MD, US
Suneet Shukla - Rockville MD, US
Suresh V. Ambudkar - Gaithersburg MD, US
Michael C. Dean - Frederick MD, US

Assignee:

THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICE - Bethesda MD

International Classification:

A61K 31/35
A61K 31/165
C07C 211/00
A61P 35/02
A61P 35/04

US Classification:

514454, 514622, 564305

Abstract:

Disclosed are methods of enhancing the chemotherapeutic treatment of tumor cells, reducing resistance of a cancer cell to a chemotherapeutic agent, a method of inhibiting ABCG2, Pgp, or MRP1 in a mammal afflicted with cancer, and a method of increasing the bioavailability of an ABCG2 substrate drug in a mammal. The methods comprise administering effective amounts of certain compounds to the mammal, for example, a compound of the formula (I): Formula (I), wherein R, R, R, X, X, X, a, and b are as described herein. Uses of these compounds in the preparation of a medicament are also disclosed. Also disclosed are compounds of formula (II), pharmaceutical compositions comprising such compounds and uses thereof.

US Patent:

20110190240, Aug 4, 2011

Filed:

Sep 22, 2009

Appl. No.:

13/120044

Inventors:

Curtis J. Henrich - Rockville MD, US
Moon-Il Kang - Gyeongsangnam-do, KR
Heidi R. Bokesch - Frederick MD, US
Kirk R. Gustafson - Frederick MD, US
Nancy H. Colburn - Middletown MD, US
Matthew R. Young - Ijamsville MD, US
James B. McMahon - Frederick MD, US

Assignee:

THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES - Bethesda MD

International Classification:

A61K 31/655
A61P 35/00
A61P 3/10
A61P 35/02
A61P 29/00
A61P 13/08
A61P 1/18
A61P 1/04
A61P 11/06
C12Q 1/02

US Classification:

514150, 435 29

Abstract:

An embodiment of the invention provides a pharmaceutical composition comprising a compound of formula (I)a pharmaceutically acceptable salt, prodrug, hydrate, or solvate thereof. Another embodiment of the invention provides a method of treating or preventing a condition associated with increased expression and/or activity of an NFκB pathway using same compounds. A further embodiment of the invention provides a method of diagnosing a condition in an individual using same compounds.

US Patent:

20130039883, Feb 14, 2013

Filed:

Dec 16, 2010

Appl. No.:

13/516514

Inventors:

Thomas Joseph Sayers - Boonsboro MD, US
Nancy Lynn Booth - Bethesda MD, US
Curtis J. Henrich - Rockville MD, US
Alan David Brooks - Frederick MD, US
Kirk R. Gustafson - Frederick MD, US
Karen L. Erickson - North Oxford MA, US

Assignee:

THE UNITED STATES OF AMERICA - 6011 EXECUTIVE SUITE 325 MC 7660 MD

International Classification:

A61K 38/19
A61P 35/00
A61K 39/395

US Classification:

424 851, 514 193, 514 189, 4241741, 514 11

Abstract:

Disclosed is a method of enhancing the response of cancer cells in a mammal to treatment with a death receptor ligand, which method comprises contacting the cancer cells with a death receptor ligand in conjunction with an effective amount of a compound described herein, for example, a cucurbitacin (I) or a withanolide (II). Also disclosed is a method of inducing apoptosis in cancer cells in a mammal, comprising contacting the cancer cells with a compound described herein, for example, a cucurbitacin (I) or a withanolide (II) and also contacting the cancer cells with a death receptor ligand, whereby apoptosis is induced in the cancer cells.

US Patent:

20190046543, Feb 14, 2019

Filed:

Feb 9, 2017

Appl. No.:

16/076954

Inventors:

- Bethesda MD, US
- Tucson AZ, US
Curtis J. Henrich - Rockville MD, US
Poonam Tewary - Frederick MD, US
James Brislin McMahon - Frederick MD, US
Leslie Gunatilaka - Tucson AZ, US
Ya-Ming Xu - Tucson AZ, US
Kithsiri Wijeratne - Tucson AZ, US

Assignee:

The United States of America, as represented by the Secretary, Department of Healthe and Human - Bethesda MD
Arizona Board of Regents on Behalf of the University of Arizona - Tucson AZ

International Classification:

A61K 31/585
A61P 35/00
A61K 45/06

Abstract:

Disclosed is a method of enhancing the response of cancer cells in a mammal to treatment with an apoptosis inducing ligand, which method comprises contacting the cancer cells with an apoptosis inducing ligand in conjunction with an effective amount of a compound of the formula: (I), wherein R-Rare as described herein. Also disclosed is a method of inducing apoptosis in cancer cells in a mammal, comprising contacting the cancer cells with the compound described herein and also contacting the cancer cells with an apoptosis inducing ligand, whereby apoptosis is induced in the cancer cells.